Juliusz Rakowski starts as CEO of BBS: "My focus is already on the time after receiving the CE marking”
BBS-Bioactive Bone Substitutes Oyj, Investor News, 15 November 2023 at 12.50 p.m.
Last week, Juliusz Rakowski officially started as CEO of BBS-Bioactive Bone Substitutes Oyj (BBS). The first week included getting to know the personnel and owners as well as the company's offices and production facilities in Oulu and Reisijärvi.
In the very beginning, Juliusz's focus will be strictly on finalizing the CE marking process of the company's first product, currently in its final stages, but under his leadership, the company is already determinedly planning steps related to the upcoming commercial phase.
“Artebone has hardly any competitors on the EU market”
Having become familiar with BBS and its first product, ARTEBONE® Paste, Juliusz believes that the company's solution has the potential to displace the currently common single-component solutions, so-called synthetic bone fillers.
"There are currently over 600 of these synthetic solutions on the market. ARTEBONE's unique competitive advantage over them is that it combines bone minerals with bone growth factors, which makes it as effective as when using the patient's own bone graft. The synthetic solutions currently on the market do not contain growth factors. That's why ARTEBONE has hardly any competitors on the EU market," describes Juliusz.
The new CEO is satisfied with the progress of the CE marking process
Juliusz has followed BBS's journey and, despite past delays, is satisfied with the progress of the CE marking process. Earlier in the spring, the approval of the product classification was the most important milestone for the company so far.
ARTEBONE was a new type of borderline case between a medical device and medicines, and the company became a significant precedent from a regulatory point of view on how such products can overall be given approvals. This is also evidenced by the fact that the company was even included as an example in the industry manual published in 2018 (Manual on borderline and classification in the community regulatory framework for medical devices, version 1.19 (04 2018)).
Just before Juliusz started (company bulletin 2 November 2023) the company received information from the Notified Body that the approval of the quality system was expected sooner than had been previously announced. According to the new CEO, this further reduced the remaining risks related to the schedule.
"It is the company’s management’s view, that we are at a stage where the technical requirements have mostly been fulfilled and it is now mostly about the schedule. What remains is the consultation of the Finnish Medicines Agency starting this month and the official product approval is proceeding alongside it. We still expect to receive the final CE marking during the second quarter of 2024, hopefully sooner of course.”
The implementation of the new industry-wide MDR regulation in 2022 was poorly timed for the company and its peers, as approvals could no longer be granted based on documentation prepared under the old regulation. Furthermore, the delays caused by Brexit and the Covid-19 pandemic are now behind us.
"Each company has been impacted by the backlog in official processing, leading to significant delays and uncertainty in their CE marking processes. However, progress is now being made."
The CEO's focusis already on the product launch
Juliusz is already looking beyond the CE marking phase, aiming to steer the company decisively into the next stage, which includes the product launch, establishing a distribution network, and market expansion.
"With over 15 years of experience in commercial roles within the life sciences industry, I think it is important that we rapidly advance developing our marketing and sales functions. I am confident that my expertise will benefit the company in this endeavor. Of course, we will do this in the most cost-effective manner, staying within the financial boundaries set by the company's funding."
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group N.V. publishes its 2024 Corporate Calendar29.11.2023 18:30:00 CET | Press release
Turin, 29th November 2023. Iveco Group N.V. (EXM: IVG) announces the following corporate calendar dates for 2024: DateEarnings releases9th FebruaryResults for 4th quarter and preliminary annual results 202310th MayResults for 1st quarter 202425th JulyResults for 2nd quarter and 1st half 20247th NovemberResults for 3rd quarter 2024 The Annual General Meeting for the approval of Iveco Group N.V.’s Financial Statements at 31st December 2023 is scheduled to take place in mid April 2024 (*). The 2024 corporate calendar is available on the corporate website: www.ivecogroup.com. (*) In compliance with the requirements set forth by the lnstructions of the Regulation of Borsa Italiana S.p.A., please note that, should the Annual General Meeting resolve a dividend related to the 2023 financial year, the month planned for the dividend detachment (ex-date) would be April. This information is provided for the aforesaid regulatory provisions only and it cannot be interpreted in any way as a forecast
PUBLICATION OF A TRANSPARENCY NOTIFICATION29.11.2023 18:30:00 CET | Press release
Publication on November 29, 2023 at 18:30 CET after market closing Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) PUBLICATION OF A TRANSPARENCY NOTIFICATION (Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings) On November 27, 2023, EVS Broadcast Equipment has received a transparency notification indicating that Otus Capital Management Limited now holds 4.99% of the voting rights of the company. Otus Capital Management Limited has therefore crossed down the threshold of 5%. The notification, dated November 27, 2023, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotification by: A parent undertaking or a controlling personPersons subject to the notification requirement: Otus Capital Management Limited, 29 Queen Anne’s Gate, London SW1H 9BU, UK; Andrew GibbsTransaction date: November 24, 2023Threshold that
IDEX - Disclosure of large shareholding - 29 Nov 202329.11.2023 18:30:00 CET | Press release
Reference is made to the announcement by IDEX Biometrics ASA on 15 November 2023 regarding a private placement of shares, and the announcement by Sundt AS on 16 November 2023 regarding lending of shares. As a result of the re-delivery of shares, Sundt AS discloses the following information pursuant to Section 4-2 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations: On 29 November 2023, following re-delivery of 45,000,000 shares in IDEX, Sundt AS’s holdings of shares increased from 61,512,922 shares to 106,512,922 which represents 7.6% of the share capital based on 1,396,621,040 shares in issue following the private placement. This notice was published by Erling Svela, Vice president of finance, on 29 November 2023 at 18:30 CET on behalf of IDEX Biometrics ASA.
SMISS launched its electronic vapor gadgets technology platform TempSure™, the world's 1st cannabis vape hardware featuring intelligent duplex communication29.11.2023 18:00:00 CET | Press release
SHENZHEN, China, Nov. 29, 2023 (GLOBE NEWSWIRE) -- As one of the largest exhibitions in the global cannabis industry, the MJBizCon 2023 CBD/THC/Cannabis Expo opened in Las Vegas as scheduled. On November 29th local time, SMISS officially launched the World's 1st Cannabis Vape Hardware Featuring Intelligent Duplex Communication, TempSure™ at the event. The platform utilizes advanced technology to provide users with the best intelligent vaporization experience. The name TempSure™ implies precise vaporization temperature control, offering users the perfect CBD vaporization experience. TempSure™ has developed an intelligent MCU control chip and a proprietary PID dynamic compensation technology solution. By accurately monitoring the heating state of CeramicMesh™ coil vaporization (oil conductivity, oil temperature, and smoke signal), it dynamically adjusts the optimal power energy output to achieve accurate heating temperature control for scientific vaporization. This enables users to exper
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: publication of a transparency notification29.11.2023 18:00:00 CET | Press release
Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant la communication relative à une notification de transparence. Attachments ENG_transparency notification_20231128_FINNL_transparency notification_20231128_FINFR_transparency notification_20231128_FIN